---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069301"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:55:01.386371+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics Q1 net loss $18.2M; VMT-α-NET cohort enrollment reaches 40 patients

## Summary
- Net loss $18.2M ($0.25 loss per share) vs $12.3M loss in prior year; R&D spend +92% to $14.3M.
- Cash $212M as of March 31; expects funding into late 2026; sold $10.2M in ATM shares in Feb 2025 at ~$3.02/share.
- VMT-α-NET: 40 patients enrolled in Cohort 2 as of April 30; data accepted for oral ASCO 2025 presentation.
- VMT01: first patient treated at new monotherapy dose level (April 2025) and in combo with nivolumab (March 2025).
- PSV359: first patient dosed; three new U.S. manufacturing sites underway for future commercial demand.

## SEC filing metadata
- accession: 0000950170-25-069301
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025069301/0000950170-25-069301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025069301/catx-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069301
- JSON: https://secwatch.observer/filing/0000950170-25-069301.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069301.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.